DEVELOPMENT OF NOVEL, NON‐TOXIC RIFAMYCINS THAT REVERSE DRUG RESISTANCE IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (June 2017) - Maxwell, S.A.